A Safety and Pharmacokinetic Study of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
Conditions: Non-Hodgkin Lymphoma; Follicular Lymphoma; DLBCL; Mantle Cell Lymphoma; Marginal Zone Lymphoma Intervention: Drug: IGM-2323 Sponsor: IGM Biosciences, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials